552 related articles for article (PubMed ID: 15743035)
21. Syndecan-1 expression has prognostic significance in head and neck carcinoma.
Anttonen A; Kajanti M; Heikkilä P; Jalkanen M; Joensuu H
Br J Cancer; 1999 Feb; 79(3-4):558-64. PubMed ID: 10027330
[TBL] [Abstract][Full Text] [Related]
22. Syndecan-1 and syndecan-4 are overexpressed in an estrogen receptor-negative, highly proliferative breast carcinoma subtype.
Baba F; Swartz K; van Buren R; Eickhoff J; Zhang Y; Wolberg W; Friedl A
Breast Cancer Res Treat; 2006 Jul; 98(1):91-8. PubMed ID: 16636895
[TBL] [Abstract][Full Text] [Related]
23. Association of syndecan-1 with tumor grade and histology in primary invasive cervical carcinoma.
Rintala M; Inki P; Klemi P; Jalkanen M; Grénman S
Gynecol Oncol; 1999 Dec; 75(3):372-8. PubMed ID: 10600292
[TBL] [Abstract][Full Text] [Related]
24. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
25. Expression and characterization of minican, a recombinant syndecan-1 with extensively truncated core protein.
Viklund L; Loo BM; Hermonen J; El-Darwish K; Jalkanen M; Salmivirta M
Biochem Biophys Res Commun; 2002 Jan; 290(1):146-52. PubMed ID: 11779146
[TBL] [Abstract][Full Text] [Related]
26. The level of syndecan-1 expression is a distinguishing feature in behavior between keratoacanthoma and invasive cutaneous squamous cell carcinoma.
Mukunyadzi P; Sanderson RD; Fan CY; Smoller BR
Mod Pathol; 2002 Jan; 15(1):45-9. PubMed ID: 11796840
[TBL] [Abstract][Full Text] [Related]
27. Syndecan-1 expression in locally invasive and metastatic prostate cancer.
Chen D; Adenekan B; Chen L; Vaughan ED; Gerald W; Feng Z; Knudsen BS
Urology; 2004 Feb; 63(2):402-7. PubMed ID: 14972511
[TBL] [Abstract][Full Text] [Related]
28. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
Matsuda K; Maruyama H; Guo F; Kleeff J; Itakura J; Matsumoto Y; Lander AD; Korc M
Cancer Res; 2001 Jul; 61(14):5562-9. PubMed ID: 11454708
[TBL] [Abstract][Full Text] [Related]
29. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells.
Reimers N; Zafrakas K; Assmann V; Egen C; Riethdorf L; Riethdorf S; Berger J; Ebel S; Jänicke F; Sauter G; Pantel K
Clin Cancer Res; 2004 May; 10(10):3422-8. PubMed ID: 15161697
[TBL] [Abstract][Full Text] [Related]
30. Developmental and FGF-2-mediated regulation of syndecans (1-4) and glypican in oligodendrocytes.
Bansal R; Kumar M; Murray K; Pfeiffer SE
Mol Cell Neurosci; 1996 Apr; 7(4):276-88. PubMed ID: 8793863
[TBL] [Abstract][Full Text] [Related]
31. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression.
Nikolova V; Koo CY; Ibrahim SA; Wang Z; Spillmann D; Dreier R; Kelsch R; Fischgräbe J; Smollich M; Rossi LH; Sibrowski W; Wülfing P; Kiesel L; Yip GW; Götte M
Carcinogenesis; 2009 Mar; 30(3):397-407. PubMed ID: 19126645
[TBL] [Abstract][Full Text] [Related]
32. Focal adhesion kinase (FAK) immunocytochemical expression in breast ductal invasive carcinoma (DIC): correlation with clinicopathological parameters and tumor proliferative capacity.
Theocharis SE; Klijanienko JT; Padoy E; Athanassiou S; Sastre-Garau XX
Med Sci Monit; 2009 Aug; 15(8):BR221-6. PubMed ID: 19644410
[TBL] [Abstract][Full Text] [Related]
33. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
34. Comparison of extracellular matrix and apoptotic markers between benign lesions and carcinomas in human breast.
Vasaturo F; Sallusti E; Gradilone A; Malacrino C; Nardo T; Avagnano G; Aglianò AM; Granato T; De Vincenzi B; Coppotelli G; Marzullo A; Soda G; Simonelli L; Modesti M; Scarpa S
Int J Oncol; 2005 Oct; 27(4):1005-11. PubMed ID: 16142317
[TBL] [Abstract][Full Text] [Related]
35. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
36. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
37. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
38. Adhesion of B lymphoid (MPC-11) cells to type I collagen is mediated by integral membrane proteoglycan, syndecan.
Sanderson RD; Sneed TB; Young LA; Sullivan GL; Lander AD
J Immunol; 1992 Jun; 148(12):3902-11. PubMed ID: 1602136
[TBL] [Abstract][Full Text] [Related]
39. Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Mylona EE; Alexandrou PT; Giannopoulou IA; Rafailidis PI; Markaki S; Keramopoulos A; Nakopoulou LL
Cancer Detect Prev; 2006; 30(2):111-7. PubMed ID: 16632244
[TBL] [Abstract][Full Text] [Related]
40. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]